Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Fowlpox and Vaccinia Virus PSA Vaccines in Advanced Prostate Cancer
NCT00005039Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2000
- Primary completion
- Mar 2007
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PROSTVAC-F/TRICOM, rilimogene galvacirepvec in prostate cancer (PCa), sponsored by National Cancer Institute. Started Jan 2000; status: terminated.
02
Drugs
PROSTVAC-F/TRICOMrilimogene galvacirepvec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005039.